Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Pediatr Gastroenterol Nutr ; 72(6): 807-814, 2021 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-33605666

RESUMO

OBJECTIVE: Increased mortality risk because of severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) infection in adults with native liver disease (LD) and liver transplant (LT) is associated with advanced age and comorbid conditions. We aim to report outcomes for children with LD and LT enrolled in the NASPGHAN/SPLIT SARS-CoV2 registry. METHODS: In this multicenter observational cohort study, we collected data from 91 patients <21 years (LD 44, LT 47) with laboratory-confirmed SARS-CoV2 infection between April 21 and September 17, 2020. RESULTS: Patients with LD were more likely to require admission (70% vs 43% LT, P = 0.007) and pediatric intensive care unit (PICU) management (32% vs 4% LT, P = 0.001). Seven LD patients required mechanical ventilation (MV) and 2 patients died; no patients in the LT cohort died or required MV. Four LD patients presented in pediatric acute liver failure (PALF), 2 with concurrent multisystem inflammatory syndrome in children (MIS-C); all recovered without LT. Two LD patients had MIS-C alone and 1 patient died. Bivariable logistic-regression analysis found that patients with nonalcoholic fatty LD (NAFLD) (odds ratio [OR] 5.6, P = 0.02) and LD (OR 6.1, P = 0.01, vs LT) had higher odds of severe disease (PICU, vasopressor support, MV, renal replacement therapy or death). CONCLUSIONS: Although not directly comparable, LT recipients had lower odds of severe SARS-CoV2 infection (vs LD), despite immunosuppression burden. NAFLD patients reported to the registry had higher odds of severe SARS-CoV2 disease. Future controlled studies are needed to evaluate effective treatments and further stratify LD and LT patients with SARS-CoV2 infection.


Assuntos
COVID-19 , Hepatopatias , Transplante de Fígado , Adulto , Criança , Humanos , RNA Viral , Sistema de Registros , SARS-CoV-2 , Síndrome de Resposta Inflamatória Sistêmica
2.
Pediatr Transplant ; 24(1): e13601, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31657119

RESUMO

Cell-mediated immunity to CMV, if known, could improve antiviral drug therapy in at-risk children and young adults with LT and IT. Host immunity has been measured with CMV-specific T cells, which express IFNγ, but not those which express CD154, a possible substitute for IFNγ. CMV-specific CD154+ T cells and their subsets were measured with flow cytometry after stimulating PBL from recipient blood samples with an overlapping peptide mix of CMV-pp65 antigen for up to 6 hours. CMV-specific CD154+ T cells co-expressed IFNγ in PBL from three healthy adults and averaged 3.8% (95% CI 3.2%-4.4%) in 40 healthy adults. CMV-specific T cells were significantly lower in 19 CMV DNAemic LT or IT recipients, compared with 126 non-DNAemic recipients, 1.3% (95% CI 0.8-1.7) vs 4.1 (95% CI 3.6-4.6, P < .001). All T-cell subsets demonstrated similar between-group differences. In logistic regression analysis of 46 training set samples, 12 with DNAemia, all obtained between days 0 and 60 from transplant, CMV-specific T-cell frequencies ≥1.7% predicted freedom from DNAemia with NPV of 93%. Sensitivity, specificity, and PPV were 83%, 74%, and 53%, respectively. Test performance was replicated in 99 validation samples. In 32 of 46 training set samples, all from seronegative recipients, one of 19 recipients with CMV-specific T-cell frequencies ≥1.7% experienced DNAemia, compared with 8 of 13 recipients with frequencies <1.7% (P = .001). CMV-specific CD154+ T cells are associated with freedom from DNAemia after LT and IT. Among seronegative recipients, CMV-specific T cells may protect against the development of CMV DNAemia.


Assuntos
Ligante de CD40/sangue , Citomegalovirus/imunologia , Intestinos/transplante , Transplante de Fígado , Complicações Pós-Operatórias/imunologia , Linfócitos T/virologia , Viremia/imunologia , Adolescente , Adulto , Biomarcadores/sangue , Criança , Pré-Escolar , DNA Viral/sangue , Feminino , Citometria de Fluxo , Voluntários Saudáveis , Humanos , Imunidade Celular , Lactente , Modelos Logísticos , Masculino , Complicações Pós-Operatórias/virologia , Fatores de Proteção , Valores de Referência , Fatores de Risco , Sensibilidade e Especificidade , Linfócitos T/imunologia , Linfócitos T/metabolismo , Viremia/etiologia , Adulto Jovem
3.
J Am Assoc Nurse Pract ; 31(4): 263-268, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30681651

RESUMO

Approximately 27,000 men and women are affected by human papillomavirus (HPV)-related cancer every year. The Advisory Committee for Immunization Practices and the Centers for Disease Control and Prevention (CDC) routinely recommend that adolescents receive HPV, tetanus, diphtheria, and acellular pertussis (tetanus-diphtheria-acellular pertussis [Tdap]) and meningococcal (MCV) vaccines at age 11-12 years. Although the CDC and professional organizations such as the American Academy of Pediatrics make national vaccine recommendations, according to the National Vaccine Information Center, it is the responsibility of "state health departments to make and enforce vaccine mandates for school entry." The Pennsylvania Department of Health has only mandated two of the recommended three vaccinations: Tdap and MCV. As of 2016, 92% of adolescents aged 13-17 years in Pennsylvania received the Tdap vaccine and 92.7% received the MCV. However, only 58% of females and 44.4% of males aged 13-17 years received all three doses of the HPV vaccine. A comparison of HPV vaccine rates in states with school mandates was compared with Pennsylvania rates. Human papillomavirus vaccination rates were found to be significantly higher in the District of Columbia and Rhode Island, which have HPV vaccine school-entry requirements, supporting the need for a statewide HPV mandate in Pennsylvania.


Assuntos
Vacinas contra Papillomavirus/uso terapêutico , Vacinação/legislação & jurisprudência , Adolescente , Distribuição de Qui-Quadrado , Feminino , Humanos , Masculino , Papillomaviridae/efeitos dos fármacos , Papillomaviridae/patogenicidade , Pennsylvania , Vacinação/tendências
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA